[go: up one dir, main page]

PL2352389T3 - Bifidobacterium longum - Google Patents

Bifidobacterium longum

Info

Publication number
PL2352389T3
PL2352389T3 PL09753220T PL09753220T PL2352389T3 PL 2352389 T3 PL2352389 T3 PL 2352389T3 PL 09753220 T PL09753220 T PL 09753220T PL 09753220 T PL09753220 T PL 09753220T PL 2352389 T3 PL2352389 T3 PL 2352389T3
Authority
PL
Poland
Prior art keywords
bifidobacterium longum
longum
bifidobacterium
Prior art date
Application number
PL09753220T
Other languages
English (en)
Inventor
Sinderen Douwe Van
Jun Xu
Wenzhu Steven Zhao
Raymond A Grant
Yuli Song
Charles Bascom
Duane Larry Charbonneau
Liam O'mahony
Original Assignee
Alimentary Health Ltd
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alimentary Health Ltd, Procter & Gamble filed Critical Alimentary Health Ltd
Publication of PL2352389T3 publication Critical patent/PL2352389T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • C12N1/205Bacterial isolates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C19/00Cheese; Cheese preparations; Making thereof
    • A23C19/02Making cheese curd
    • A23C19/032Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
    • A23C19/0323Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C19/00Cheese; Cheese preparations; Making thereof
    • A23C19/06Treating cheese curd after whey separation; Products obtained thereby
    • A23C19/061Addition of, or treatment with, microorganisms
    • A23C19/062Addition of, or treatment with, microorganisms using only lactic acid bacteria, e.g. pediococcus, leconostoc or bifidus sp., or propionic acid bacteria; Treatment with non-specified acidifying bacterial cultures
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23CDAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
    • A23C9/00Milk preparations; Milk powder or milk powder preparations
    • A23C9/12Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38Other non-alcoholic beverages
    • A23L2/382Other non-alcoholic beverages fermented
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135Bacteria or derivatives thereof, e.g. probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • A61K35/744Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745Bifidobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/04Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00Lactic or propionic acid bacteria
    • A23V2400/51Bifidobacterium
    • A23V2400/533Longum
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12RINDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00Microorganisms ; Processes using microorganisms
    • C12R2001/01Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Nutrition Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Enzymes And Modification Thereof (AREA)
PL09753220T 2008-11-11 2009-11-11 Bifidobacterium longum PL2352389T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11351308P 2008-11-11 2008-11-11
US14998009P 2009-02-04 2009-02-04
PCT/IE2009/000079 WO2010055499A2 (en) 2008-11-11 2009-11-11 Bifidobacterium longum
EP09753220.4A EP2352389B1 (en) 2008-11-11 2009-11-11 Bifidobacterium longum

Publications (1)

Publication Number Publication Date
PL2352389T3 true PL2352389T3 (pl) 2016-07-29

Family

ID=41572466

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09753220T PL2352389T3 (pl) 2008-11-11 2009-11-11 Bifidobacterium longum

Country Status (11)

Country Link
US (3) US9771624B2 (pl)
EP (1) EP2352389B1 (pl)
CN (1) CN102984955B (pl)
AU (1) AU2009315298A1 (pl)
BR (1) BRPI0921758A2 (pl)
CA (3) CA2852479C (pl)
ES (1) ES2566496T3 (pl)
MX (4) MX349706B (pl)
PL (1) PL2352389T3 (pl)
RU (1) RU2570557C2 (pl)
WO (1) WO2010055499A2 (pl)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090127180A (ko) * 2007-03-28 2009-12-09 앨러멘터리 헬스 리미티드 프로바이오틱 비피도박테리움 스트레인
US9771624B2 (en) 2008-11-11 2017-09-26 The Procter & Gamble Company Bifidobacterium longum
EP2283810A1 (en) 2009-07-16 2011-02-16 University College Cork-National University of Ireland, Cork Orally administered bacteria as vehicles for systemic delivery of agents
RU2546251C2 (ru) 2009-11-11 2015-04-10 Алиментари Хелс Лимитед Пробиотический штамм бифидобактерий
AU2010317423C1 (en) * 2009-11-11 2015-01-22 Alimentary Health Limited A bifidobacterium strain
US9259019B2 (en) 2010-11-11 2016-02-16 Mars, Incorporated Bifidobacteriumstrain
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
IN2014DN07752A (pl) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
US9161957B2 (en) 2012-08-03 2015-10-20 Life Well Lived, Llc Compositions and methods for reducing blood alcohol content
KR102874079B1 (ko) 2013-03-15 2025-10-22 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
KR20230054509A (ko) 2013-11-07 2023-04-24 에디타스 메디신, 인코포레이티드 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
WO2015074054A1 (en) * 2013-11-18 2015-05-21 The Trustees Of Columbia University In The City Of New York Improving microbial fitness in the mammalian gut
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
MX382478B (es) 2014-10-24 2025-03-13 Infinant Health Inc Bifidobacterias activadas y metodos de uso de las mismas.
SG10201903823QA (en) 2014-10-31 2019-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
US9913800B2 (en) 2015-04-28 2018-03-13 The Procter & Gamble Company Compositions and methods for improving skin health
CN104894005B (zh) * 2015-04-30 2018-05-22 江苏紫石微康生物科技有限公司 一种高产胞外多糖的乳酸菌bl21及制备方法和应用
RU2614116C2 (ru) * 2015-07-21 2017-03-22 Головин Михаил Анатольевич Способ получения пробиотической композиции
WO2017032897A1 (en) * 2015-08-27 2017-03-02 Alimentary Health Limited Use of bifidobacterium longum and an exopolysaccharide produced thereby
EP3341082B1 (en) 2015-08-27 2020-12-16 PrecisionBiotics Group Limited Bifidobacterium longum
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
EP3386523B1 (en) 2015-12-11 2019-10-09 Alimentary Health Limited Bifidobacterium longum for treating obesity and associated metabolic disorders
CN105907682A (zh) * 2016-05-31 2016-08-31 深圳先进技术研究院 一种产高粘性多糖的细菌的筛选方法
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
EP4154722A1 (en) 2018-01-29 2023-03-29 PrecisionBiotics Group Limited A combination product for prophylaxis and treatment of irritable bowel syndrome
CN111902155B (zh) * 2018-01-29 2024-08-02 精密生物集团有限公司 长双歧杆菌ncimb 41676
WO2019145574A1 (en) * 2018-01-29 2019-08-01 Alimentary Health Limited Bifidobacterium longum ncimb 41676
CN111918663B (zh) 2018-01-29 2024-10-11 精密生物集团有限公司 长双歧杆菌ncimb 41676
US20200289588A1 (en) * 2018-01-29 2020-09-17 Precisionbiotics Group Limited Bifidobacterium longum ncimb 41676
GB2590272B (en) 2018-07-13 2022-08-31 Council Scient Ind Res Synbiotic composition for improving immune response and antioxidant capacity during aging and a process for the preparation thereof
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
US11752178B2 (en) 2019-04-17 2023-09-12 Nutech Ventures Methods for the isolation of microbes with enhanced persistance and compositions with such microbes
CN110205393B (zh) * 2019-07-03 2020-07-24 南京先声医学检验有限公司 用于检测营养代谢能力相关snp位点的引物组、应用、产品及方法
JP7013419B2 (ja) * 2019-08-07 2022-02-15 日清食品ホールディングス株式会社 炎症性サイトカインの産生誘導活性は低いが抗炎症性サイトカインの産生誘導活性が高いビフィズス菌
WO2021077543A1 (zh) * 2019-10-23 2021-04-29 江南大学 一种亚油酸异构酶及其在共轭亚油酸生产中的应用
CN112391484B (zh) * 2020-11-17 2022-12-27 江南大学 一种定量检测长双歧杆菌菌株的方法
US20250312388A1 (en) * 2022-01-12 2025-10-09 Tahmeed Ahmed Bifidobacterium infantis formulations
CN114507649B (zh) * 2022-02-16 2023-11-21 吉林大学 嗜热酶及一锅法高效合成udp-葡萄糖和udp-葡萄糖醛酸的方法
CN114774335B (zh) * 2022-06-22 2022-09-02 广东省科学院微生物研究所(广东省微生物分析检测中心) 具有靶向葡萄糖激酶显著降血糖和降血脂功效的长双歧杆菌070103及其应用
CN117568301B (zh) * 2023-11-16 2024-05-10 安徽农业大学 一种通过糖多孢红霉菌sace_1646基因提高红霉素产量的方法
CN118086539B (zh) * 2024-03-05 2024-10-01 中国食品发酵工业研究院有限公司 长双歧杆菌婴儿亚种的PMA-qPCR活菌定量检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US20010049115A1 (en) 2000-01-17 2001-12-06 Collins John Kevin Vitro model for gastrointestinal inflammation
EP1227152A1 (en) * 2001-01-30 2002-07-31 Société des Produits Nestlé S.A. Bacterial strain and genome of bifidobacterium
ES2381211T3 (es) 2006-02-15 2012-05-24 Nestec S.A. Uso del Bifidobacterium longum para prevenir y tratar inflamaciones
RU2333655C2 (ru) * 2006-07-26 2008-09-20 Государственное образовательное учреждение высшего профессионального образования Восточно-Сибирский государственный технологический университет Способ получения селенсодержащей биологически активной добавки
DK2318513T3 (da) * 2008-07-11 2012-10-22 Chr Hansen As Ny probiotisk bifidobacterium longum
US9771624B2 (en) 2008-11-11 2017-09-26 The Procter & Gamble Company Bifidobacterium longum

Also Published As

Publication number Publication date
CA2741942A1 (en) 2010-05-20
RU2011120271A (ru) 2012-12-20
CA2852479C (en) 2017-01-24
MX356598B (es) 2018-06-04
MX349705B (es) 2017-08-09
US10689719B2 (en) 2020-06-23
US20100183559A1 (en) 2010-07-22
CN102984955B (zh) 2015-01-07
MX2011005006A (es) 2011-05-24
CA2741942C (en) 2018-01-16
CA2852479A1 (en) 2010-05-20
WO2010055499A2 (en) 2010-05-20
EP2352389A2 (en) 2011-08-10
RU2570557C2 (ru) 2015-12-10
CA2852487A1 (en) 2010-05-20
CA2852487C (en) 2017-01-31
US9771624B2 (en) 2017-09-26
CN102984955A (zh) 2013-03-20
US20200377961A1 (en) 2020-12-03
BRPI0921758A2 (pt) 2019-07-30
ES2566496T3 (es) 2016-04-13
MX339907B (es) 2016-06-14
WO2010055499A3 (en) 2010-09-23
EP2352389B1 (en) 2016-01-06
AU2009315298A1 (en) 2010-05-20
MX349706B (es) 2017-08-09
US20180016647A1 (en) 2018-01-18

Similar Documents

Publication Publication Date Title
PL2352389T3 (pl) Bifidobacterium longum
GB2460781B (en) Probiotic bifidobacterium strains
GB2465051B (en) Probiotic bifidobacterium strains
PL2498789T3 (pl) Probiotyczny szczep bifidobacterium
ZA201202155B (en) Bifidobacterium longum and functional gi disorders
EG25742A (en) Photobioreactor
DK2318513T3 (da) Ny probiotisk bifidobacterium longum
GB2504633B (en) Nanoemulsions
ZA201007327B (en) Synbiotic mixture
EP2262589A4 (en) CYCLONE
PL2103827T3 (pl) Połączenia wał-piasta
GB0812597D0 (en) Modified surfaces
GB0814573D0 (en) Photobioreactors
GB0913505D0 (en) Differential
EP2317180A4 (de) Abik-differential
PL380803A1 (pl) Nowy szczep Bifidobacterium longum
GB0807264D0 (en) Biocontrol
GB0810722D0 (en) mesher
GB0808074D0 (en) P2
GB0804838D0 (en) Concept six
GB0805454D0 (en) Concept eight
GB0811149D0 (en) Gene
GB0817884D0 (en) Technology predction
GB201108463D0 (en) Nanoemulsions
GB0804837D0 (en) Concept three